These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 9012640)
21. Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production. Millar JS; Maugeais C; Ikewaki K; Kolansky DM; Barrett PH; Budreck EC; Boston RC; Tada N; Mochizuki S; Defesche JC; Wilson JM; Rader DJ Arterioscler Thromb Vasc Biol; 2005 Mar; 25(3):560-5. PubMed ID: 15637307 [TBL] [Abstract][Full Text] [Related]
22. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475 [TBL] [Abstract][Full Text] [Related]
23. Pravastatin treatment of very low density, intermediate density and low density lipoproteins in hypercholesterolemia and combined hyperlipidemia secondary to the nephrotic syndrome. Toto RD; Grundy SM; Vega GL Am J Nephrol; 2000; 20(1):12-7. PubMed ID: 10644862 [TBL] [Abstract][Full Text] [Related]
24. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523 [TBL] [Abstract][Full Text] [Related]
25. Human apolipoprotein (Apo) B-48 and ApoB-100 kinetics with stable isotopes. Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2966-74. PubMed ID: 10591677 [TBL] [Abstract][Full Text] [Related]
26. Effect of apolipoprotein E genotype on apolipoprotein B-100 metabolism in normolipidemic and hyperlipidemic subjects. Ooi EM; Janus ED; Grant SJ; Sinclair LM; R Barrett PH J Lipid Res; 2010 Aug; 51(8):2413-21. PubMed ID: 20413671 [TBL] [Abstract][Full Text] [Related]
27. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity. Chan DC; Watts GF; Barrett PH; Mori TA; Beilin LJ; Redgrave TG J Clin Endocrinol Metab; 2002 May; 87(5):2283-9. PubMed ID: 11994377 [TBL] [Abstract][Full Text] [Related]
28. Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome. Chan DC; Watts GF; Barrett PH; O'Neill FH; Thompson GR Obes Res; 2003 Apr; 11(4):591-6. PubMed ID: 12690090 [TBL] [Abstract][Full Text] [Related]
30. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages. Milosavljevic D; Griglio S; Le Naour G; Chapman MJ Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449 [TBL] [Abstract][Full Text] [Related]
31. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. Packard CJ; Demant T; Stewart JP; Bedford D; Caslake MJ; Schwertfeger G; Bedynek A; Shepherd J; Seidel D J Lipid Res; 2000 Feb; 41(2):305-18. PubMed ID: 10681415 [TBL] [Abstract][Full Text] [Related]
32. Metabolism of apolipoprotein B-100 in a kindred with familial hypobetalipoproteinemia without a truncated form of apoB. Latour MA; Patterson BW; Pulai J; Chen Z; Schonfeld G J Lipid Res; 1997 Mar; 38(3):592-9. PubMed ID: 9101440 [TBL] [Abstract][Full Text] [Related]
33. Determination of kinetic parameters of apolipoprotein B metabolism using amino acids labeled with stable isotopes. Parhofer KG; Hugh P; Barrett R; Bier DM; Schonfeld G J Lipid Res; 1991 Aug; 32(8):1311-23. PubMed ID: 1770313 [TBL] [Abstract][Full Text] [Related]
34. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Chan DC; Watts GF; Barrett PH; Beilin LJ; Redgrave TG; Mori TA Diabetes; 2002 Aug; 51(8):2377-86. PubMed ID: 12145148 [TBL] [Abstract][Full Text] [Related]
35. Increased clearance of low density lipoprotein precursors in patients with heterozygous familial defective apolipoprotein B-100: a stable isotope approach. Pietzsch J; Wiedemann B; Julius U; Nitzsche S; Gehrisch S; Bergmann S; Leonhardt W; Jaross W; Hanefeld M J Lipid Res; 1996 Oct; 37(10):2074-87. PubMed ID: 8906585 [TBL] [Abstract][Full Text] [Related]
36. TRL, IDL, and LDL apolipoprotein B-100 and HDL apolipoprotein A-I kinetics as a function of age and menopausal status. Matthan NR; Jalbert SM; Lamon-Fava S; Dolnikowski GG; Welty FK; Barrett HR; Schaefer EJ; Lichtenstein AH Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1691-6. PubMed ID: 15933247 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs. Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2589-600. PubMed ID: 9409231 [TBL] [Abstract][Full Text] [Related]